These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21198274)

  • 21. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
    Huang YS; Wu JC; Chan CY; Chao Y; Chang FY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug; 62(8):487-95. PubMed ID: 10462824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
    Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
    Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of serum hepatocyte growth factor levels in liver diseases.
    Hioki O; Watanabe A; Minemura M; Tsuchida T
    J Med; 1993; 24(1):35-46. PubMed ID: 7684768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Morota K; Nakagawa M; Sekiya R; Hemken PM; Sokoll LJ; Elliott D; Chan DW; Dowell BL
    Clin Chem Lab Med; 2011 Apr; 49(4):711-8. PubMed ID: 21231906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
    Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
    Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma.
    Abbasi A; Bhutto AR; Butt N; Munir SM
    J Pak Med Assoc; 2012 Jan; 62(1):33-6. PubMed ID: 22352098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
    Ali MA; Koura BA; el-Mashad N; Zaghloul MH
    Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
    Izuno K; Fujiyama S; Yamasaki K; Sato M; Sato T
    Hepatogastroenterology; 1995; 42(4):387-93. PubMed ID: 8586374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
    Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
    Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease.
    Newsome PN; Beldon I; Moussa Y; Delahooke TE; Poulopoulos G; Hayes PC; Plevris JN
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1295-301. PubMed ID: 11012474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
    Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
    Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.
    Cheng KS; Tang HL; Chou FT; Chou JW; Hsu CH; Yu CJ; Kao ST; Li TC
    Hepatogastroenterology; 2009; 56(93):1105-10. PubMed ID: 19760951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
    Helaly GF; Abou Shamaa LA
    Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
    Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
    Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma.
    Edis C; Kähler C; Klotz W; Herold M; Feichtinger H; Königsreiner A; Margreiter R; Jaschke W; Vogel W
    Transplant Proc; 1998 May; 30(3):780-1. PubMed ID: 9595095
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon-gamma is associated with hepatic dysfunction in fibrosis, cirrhosis, and hepatocellular carcinoma.
    Attallah AM; El-Far M; Zahran F; Shiha GE; Farid K; Omran MM; Abdelrazek MA; Attallah AA; El-Beh AA; El-Hosiny RM; El-Waseef AM
    J Immunoassay Immunochem; 2016; 37(6):597-610. PubMed ID: 27093468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serum anti-Ku86: a potential biomarker for early detection of hepatocellular carcinoma].
    Chu L; Zhang X; Wang G; Zhou W; Du Z; Liu A; Zhao H
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):123-7. PubMed ID: 24796461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.